Appointments Jobs About Search Education & Research Clinical Trials Health Information Medical Services

Publications - John N . Caviness, M.D.

Back to Research Profile

  1. Driver-Dunckley E, Connor D, Hentz J, Sabbagh M, Silverberg N, Hernandez J, Vedders L, Evidente VG, Shill H, Caviness J, Adler C. No evidence for cognitive dysfunction or depression in patients with mild restless legs syndrome. Mov Disord 2009 Sep 15; 24(12):1840-2.
    View PubMed
  2. Caviness JN. Pathophysiology and treatment of myoclonus. Neurol Clin 2009 Aug; 27(3):757-77, vii.
    View PubMed
  3. Sabbagh MN, Adler CH, Lahti TJ, Connor DJ, Vedders L, Peterson LK, Caviness JN, Shill HA, Sue LI, Ziabreva I, Perry E, Ballard CG, Aarsland D, Walker DG, Beach TG. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord 2009 Jul-Sep; 23(3):295-7.
    View PubMed
  4. Sabbagh MN, Sandhu SS, Farlow MR, Vedders L, Shill HA, Caviness JN, Connor DJ, Sue L, Adler CH, Beach TG. Correlation of clinical features with argyrophilic grains at autopsy. Alzheimer Dis Assoc Disord 2009 Jul-Sep; 23(3):229-33.
    View PubMed
  5. Almaraz AC, Driver-Dunckley ED, Woodruff BK, Wellik KE, Caselli RJ, Demaerschalk BM, Adler CH, Caviness JN, Wingerchuk DM. Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. Neurologist 2009 Jul; 15(4):234-7.
    View PubMed
  6. Alvarez MV, Driver-Dunckley EE, Caviness JN, Adler CH, Evidente VG. Case series of painful legs and moving toes: clinical and electrophysiologic observations. Mov Disord 2008 Oct 30; 23(14):2062-6.
    View PubMed
  7. Alvarez M, Caviness JN. Primary progressive myoclonus of aging. Mov Disord 2008 Sep 15; 23(12):1658-64.
    View PubMed
  8. Stamper C, Siegel A, Liang WS, Pearson JV, Stephan DA, Shill H, Connor D, Caviness JN, Sabbagh M, Beach TG, Adler CH, Dunckley T. Neuronal gene expression correlates of Parkinson's disease with dementia. Mov Disord 2008 Aug 15; 23(11):1588-95.
    View PubMed
  9. Shill HA, Adler CH, Sabbagh MN, Connor DJ, Caviness JN, Hentz JG, Beach TG. Pathologic findings in prospectively ascertained essential tremor subjects. Neurology 2008 Apr 15; 70(16 Pt 2):1452-5.
    View PubMed
  10. Beach TG, Adler CH, Sue LI, Peirce JB, Bachalakuri J, Dalsing-Hernandez JE, Lue LF, Caviness JN, Connor DJ, Sabbagh MN, Walker DG. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol 2008 Apr; 115(4):445-51. Epub 2007 Nov 06.
    View PubMed
  11. McKinnon JH, Demaerschalk BM, Caviness JN, Wellik KE, Adler CH, Wingerchuk DM. Sniffing out Parkinson disease: can olfactory testing differentiate parkinsonian disorders? Neurologist 2007 Nov; 13(6):382-5.
    View PubMed
  12. Beach TG, Sue LI, Walker DG, Lue LF, Connor DJ, Caviness JN, Sabbagh MN, Adler CH. Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits. Acta Neuropathol (Berl) 2007 Oct; 114(4):419-24. Epub 2007 Jul 17.
    View PubMed
  13. Driver-Dunckley ED, Noble BN, Hentz JG, Evidente VG, Caviness JN, Parish J, Krahn L, Adler CH. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 2007 Sep-Oct; 30(5):249-55.
    View PubMed
  14. Caviness JN, Hentz JG, Evidente VG, Driver-Dunckley E, Samanta J, Mahant P, Connor DJ, Sabbagh MN, Shill HA, Adler CH. Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease. Parkinsonism Relat Disord 2007 Aug; 13(6):348-54. Epub 2007 Mar 08.
    View PubMed
  15. Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, Evidente VG, Shill HA, Adler CH. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007 Jul 15; 22(9):1272-7.
    View PubMed
  16. Arvanitakis Z, Witte RJ, Dickson DW, Tsuboi Y, Uitti RJ, Slowinski J, Hutton ML, Lin SC, Boeve BF, Cheshire WP, Pooley RA, Liss JM, Caviness JN, Strongosky AJ, Wszolek ZK. Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation). Parkinsonism Relat Disord 2007 May; 13(4):230-9 Epub 2006 Dec 29.
    View PubMed
  17. Caviness JN. Parkinsonism & related disorders. Myoclonus. Parkinsonism Relat Disord 2007; 13 Suppl 3:S375-84.
    View PubMed
  18. Sabbagh MN, Lahti T, Connor DJ, Caviness JN, Shill H, Vedders L, Mahant P, Samanta J, Burns RS, Evidente VG, Driver-Dunckley E, Reisberg B, Bircea S, Adler CH. Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's disease. Dement Geriatr Cogn Disord 2007; 24(5):327-34. Epub 2007 Sep 13.
    View PubMed
  19. Liss JM, Krein-Jones K, Wszolek ZK, Caviness JN. Speech characteristics of patients with pallido-ponto-nigral degeneration and their application to presymptomatic detection in at-risk relatives. Am J Speech Lang Pathol 2006 Aug; 15(3):226-35.
    View PubMed
  20. Hoffman Snyder C, Mishark KJ, Caviness JN, Drazkowski JF, Caselli RJ. Nonvasculitic autoimmune inflammatory meningoencephalitis imitating Creutzfeldt-Jakob disease. Arch Neurol 2006 May; 63(5):766-8.
    View PubMed
  21. Caviness JN, Liss JM, Adler C, Evidente V. Analysis of high-frequency electroencephalographic-electromyographic coherence elicited by speech and oral nonspeech tasks in Parkinson's disease. J Speech Lang Hear Res 2006 Apr; 49(2):424-38.
    View PubMed
  22. Caviness JN, Shill HA, Sabbagh MN, Evidente VG, Hernandez JL, Adler CH. Corticomuscular coherence is increased in the small postural tremor of Parkinson's disease. Mov Disord 2006 Apr; 21(4):492-9.
    View PubMed
  23. Sabbagh MN, Silverberg N, Bircea S, Majeed B, Samant S, Caviness JN, Reisberg B, Adler CH. Is the functional decline of Parkinson's disease similar to the functional decline of Alzheimer's disease? Parkinsonism Relat Disord 2005 Aug; 11(5):311-5.
    View PubMed
  24. Tsuboi Y, Josephs KA, Boeve BF, Litvan I, Caselli RJ, Caviness JN, Uitti RJ, Bott AD, Dickson DW. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Mov Disord 2005 Aug; 20(8):982-8.
    View PubMed
  25. Badhwar A, Berkovic SF, Dowling JP, Gonzales M, Narayanan S, Brodtmann A, Berzen L, Caviness J, Trenkwalder C, Winkelmann J, Rivest J, Lambert M, Hernandez-Cossio O, Carpenter S, Andermann F, Andermann E. Action myoclonus-renal failure syndrome: characterization of a unique cerebro-renal disorder. Brain 2004 Oct; 127(Part 10):2173-82.
    View PubMed
  26. Caviness JN, Brown P. Myoclonus: current concepts and recent advances. Lancet Neurology 2004 Oct; 3(10):598-607.
    View PubMed
  27. Adler CH, Bansberg SF, Hentz JG, Ramig LO, Buder EH, Witt K, Edwards BW, Krein-Jones K, Caviness JN. Botulinum toxin type A for treating voice tremor. Arch Neurol 2004 Sep; 61(9):1416-20.
    View PubMed
  28. Adler CH, Hauser RA, Sethi K, Caviness JN, Marlor L, Anderson WM, Hentz JG. Ropinirole for restless legs syndrome - A placebo-controlled crossover trial. Neurology 2004 Apr 27; 62(8):1405-7.
    View PubMed
  29. Huntington Study Group, et al, Caviness JN. Minocycline safety and tolerability in Huntington's disease. Neurology 2004; 63:547-9.
    View PubMed
  30. Caviness JN, Adler CH, Sabbagh MN, Connor DJ, Hernandez JL, Lagerlund TD. Abnormal corticomuscular coherence is associated with the small amplitude cortical myoclonus in Parkinson's disease. Mov Disord 2003 Oct; 18(10):1157-62.
    View PubMed
  31. Evidente VGH, Caviness JN, Adler CH. Case studies in movement disorders. Semin Neurol 2003 Sep; 23(3):277-84.
    View PubMed
  32. Caviness JN. Myoclonus and neurodegenerative disease - what's in a name? Parkinsonism & Related Disorders 2003 Mar; 9(4):185-92.
    View PubMed
  33. Caviness JN, Evidente VGH. Cortical myoclonus during lithium exposure. Arch Neurol 2003 Mar; 60(3):401-4.
    View PubMed
  34. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003 Mar; 18(3):287-93.
    View PubMed
  35. Caviness JN, Tsuboi Y, Wszolek ZK. Clinical-electrophysiological correlation of tremor and myoclonus in a kindred with the N279K tau mutation. Parkinsonism & Related Disorders 2003 Jan; 9(3):151-7.
    View PubMed
  36. Adler CH, Hentz JG, Joyce JN, Beach T, Caviness JN. Motor impairment in normal aging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors. Parkinsonism & Related Disorders 2002 Dec; 9(2):103-10.
    View PubMed
  37. Liss JM, Spitzer SM, Caviness JN, Adler C. The effects of familiarization on intelligibility and lexical segmentation in hypokinetic and ataxic dysarthria. J Acoust Soc Am 2002 Dec; 112(6):3022-30.
    View PubMed
  38. Joyce JN, Ryoo HL, Beach TB, Caviness JN, Stacy M, Gurevich EV, Reiser M, Adler CH. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D-3 and not D-2 receptors. Brain Res 2002 Nov 15; 955(1-2):138-52.
    View PubMed
  39. Caviness JN, Adler CH, Beach TG, Wetjen KL, Caselli RJ. Small-amplitude cortical myoclonus in Parkinson's disease: Physiology and clinical observations. Mov Disord 2002 Jul; 17(4):657-62.
    View PubMed
  40. Kompoliti K, Adler CH, Raman R, Pincus JH, Leibowitz MT, Ferry JJ, Blasucci L, Caviness JN, Leurgans S, Chase WM, Yones LC, Tan E, Carvey P, Goetz CG. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology 2002 May 14; 58(9):1418-22.
    View PubMed
  41. Caviness JN, Smith BE, Stevens JC, Adler CH, Caselli RJ, Hentz JG, Manfred MS, Muenter D. Motor unit number estimates in idiopathic Parkinson's disease. Parkinsonism Relat Disord 2002 Jan; 8(3):161-4.
    View PubMed
  42. Caviness JN, Adler CH, Beach TG, Wetjen KL, Caselli RJ. Myoclonus in Lewy body disorders. Adv Neurol 2002; 89:23-30.
    View PubMed
  43. Caviness JN. Epidemiology of myoclonus. Adv Neurol 2002; 89:19-22.
    View PubMed
  44. Ahlskog JE, Nishino H, Evidente VGH, Tulloch JW, Forbes GS, Caviness JN, Gwinn-Hardy KA. Persistent chorea triggered by hyperglycemic crisis in diabetics. Mov Disord 2001 Sep; 16(5):890-898.
    View PubMed
  45. Evidente VGH, Caviness JN, Adler CH, Gwinn-Hardy KA, Pratley RE. Serum leptin concentrations and satiety in Parkinson's disease patients with and without weight loss. Mov Disord 2001 Sep; 16(5):924-927.
    View PubMed
  46. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, Dubinsky RM, Friedman JH, Manyam BV, Matsumoto JY, Pullman SL, Rajput AH, Sethi KD, Tanner C, Koller WC. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001 Jun 12; 56(11):1523-8.
    View PubMed
  47. Caviness JN. Primary care guide to myoclonus and chorea. Characteristics, causes and clinical options. Postgrad Med 2000 Oct; 108(5):163-6, 169-72.
    View PubMed
  48. Cooper C, Evidente VG, Hentz JG, Adler CH, Caviness JN, Gwinn-Hardy K. The effect of temperature on hand function in patients with tremor. J Hand Ther 2000 Oct-Dec; 13(4):276-88.
    View PubMed
  49. Liss JM, Spitzer SM, Caviness JN, Adler C, Edwards BW. Lexical boundary error analysis in hypokinetic and ataxic dysarthria. J Acoust Soc Am 2000 Jun; 107(6):3415-24.
    View PubMed
  50. Evidente VG, Gwinn-Hardy KA, Caviness JN, Gilman S. Hereditary ataxias. Mayo Clin Proc 2000 May; 75(5):475-90.
    View PubMed
  51. Caviness JN, Smith BE, Stevens JC, Adler CH, Caselli RJ, Reiners CA, Hentz JG, Muenter MD. Motor unit changes in sporadic idiopathic Parkinson's disease. Mov Disord 2000 Mar; 15(2):238-43.
    View PubMed
  52. Evidente VG, Adler CH, Caviness JN, Hentz JG, Gwinn-Hardy K. Amantadine is beneficial in restless legs syndrome. Mov Disord 2000 Mar; 15(2):324-7.
    View PubMed
  53. Gwinn-Hardy KA, Crook R, Lincoln S, Adler CH, Caviness JN, Hardy J, Farrer M. A kindred with Parkinson's disease not showing genetic linkage to established loci. Neurology 2000 Jan 25; 54(2):504-7.
    View PubMed
  54. Pratley RE, Salbe AD, Ravussin E, Caviness JN. Higher sedentary energy expenditure in patients with Huntington's disease. Ann Neurol 2000 Jan; 47(1):64-70.
    View PubMed
  55. Caviness JN, Gwinn-Hardy K, Adler CH, Muenter MD. Electrophysical observations in hereditary Parkinsonism-dementia with Lewy body pathology. Mov Disord 2000 Jan; 15(1):140-145.
    View PubMed
  56. Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB, Siemers E, Shoulson I, Caviness JN, The Huntington Study Group. Rate of functional decline in Huntington’s disease. Neurology 2000; 54:452-8.
    View PubMed
  57. Spitzer SM, Liss JM, Caviness JN, Adler CH. An exploration of familiarization effects in the perception of hypokinetic and ataxic dysarthic speech. J of Med Speech-Language Path 2000; 8:285-93.
    View PubMed
  58. Caviness JN, Alving LI, Maraganore DM, Black RA, McDonnell SK, Rocca WA. The incidence and prevalence of myoclonus in Olmsted County, Minnesota. Mayo Clin Proc 1999 Jun; 74(6):565-9.
    View PubMed
  59. Evidente VG, Caviness JN, Jamieson B, Weaver A, Joshi N. Intersubject variability and intrasubject reproducibility of the bereitschaftspotential. Mov Disord 1999 Mar; 14(2):313-9.
    View PubMed
  60. Caselli RJ, Stelmach GE, Caviness JN, Timmann D, Royer T, Boeve BF, Parisi JE. A kinematic study of progressive apraxia with and without dementia. Mov Disord 1999 Mar; 14(2):276-87.
    View PubMed
  61. Evidente VG, Gwinn-Hardy K, Caviness JN, Adler CH. Risperidone is effective in severe hemichorea/hemiballismus. Mov Disord 1999 Mar; 14(2):377-9.
    View PubMed
  62. Evidente VG, Caviness JN. Focal cortical transient preceding myoclonus during lithium and tricyclic antidepressant therapy. Neurology 1999 Jan 1; 52(1):211-3.
    View PubMed
  63. Evidente VG, Adler CH, Caviness JN, Gwinn-Hardy K. A pilot study on the motor effects of rimantadine in Parkinson's disease. Clin Neuropharmacol 1999 Jan-Feb; 22(1):30-2.
    View PubMed
  64. Liss JM, Spitzer S, Caviness JN, Adler C, Edwards B. Syllabic strength and lexical boundary decisions in the perception of hypokinetic dysarthric speech. J Acoust Soc Am 1998 Oct; 104(4):2457-66.
    View PubMed
  65. Evidente VG, Adler CH, Caviness JN, Gwinn KA. Effective treatment of orthostatic tremor with gabapentin. Mov Disord 1998 Sep; 13(5):829-31.
    View PubMed
  66. Evidente VG, Gwinn KA, Caviness JN, Hirschorn K, Deen HG. Surgically responsive focal tremor associated with a frontal convexity meningioma. Eur Neurol 1998 Aug; 40(2):107-8.
    View PubMed
  67. Caviness JN, Adler CH, Newman S, Caselli RJ, Muenter MD. Cortical myoclonus in levodopa-responsive parkinsonism. Mov Disord 1998 May; 13(3):540-4.
    View PubMed
  68. Evidente VG, Gwinn KA, Caviness JN, Muenter M, Mulder DW. Early cinematographic cases of postencephalitic parkinsonism and other movement disorders. Mov Disord 1998 Jan; 13(1):167-9.
    View PubMed
  69. Caviness JN, Kurth M. Cortical Myoclonus in Huntington's disease associated with an enlarged somatosensory evoked potential. Mov Disord 1997 Nov; 12(6):1046-51.
    View PubMed
  70. Uitti RJ, Wharen RE Jr, Turk MF, Lucas JA, Finton MJ, Graff-Radford NR, Boylan KB, Goerss SJ, Kall BA, Adler CH, Caviness JN, Atkinson EJ. Unilateral pallidotomy for Parkinson's disease: comparison of outcome in younger versus elderly patients. Neurology 1997 Oct; 49(4):1072-7.
    View PubMed
  71. Adler CH, Caviness JN. Dystonia secondary to electrical injury: surface electromyographic evaluation and implications for the organicity of the condition. J Neurol Sci 1997 May 29; 148(2):187-92.
    View PubMed
  72. Gwinn KA, Caviness JN. Electrophysiological observations in idiopathic opsoclonus-myoclonus syndrome. Mov Disord 1997 May; 12(3):438-42.
    View PubMed
  73. Gwinn KA, Caviness JN. Risperidone-induced tardive dyskinesia and parkinsonism. Mov Disord 1997 Jan; 12(1):119-21.
    View PubMed
  74. Kurth MC, Adler CH, Sthilaire M, Singer C, Waters C, Lewitt P, Chernik DA, Dorflinger EE, Yoo K, Lieberman AN, Brewer M, Sainthilaire M, Pery LM, Thomas C, Turpin L, Obrien CF, Seeberger LC, Duncan KL, Caviness JN, Douglas M, Wheeler K, Riley D, Rainey P, Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations - a multicenter, double blind, randomized, placebo-controlled trial. Neurology 1997 Jan; 48(1):81-87.
    View PubMed
  75. Lieberman A, Caviness JN, The Pramipexole Study Group. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controled, parallel-group study. Neurology 1997; 49(162-8).
  76. Weber JG, Cunnien AJ, Hinni ML, Caviness JN. Psychogenic coma after use of general anesthesia for ethmoidectomy. Mayo Clin Proc 1996 Aug; 71(8):797-800.
    View PubMed
  77. Caviness JN. Myoclonus. Mayo Clin Proc 1996 Jul; 71(7):679-88.
    View PubMed
  78. Caviness JN, Forsyth PA, Layton DD, McPhee TJ. The movement disorder of adult opsoclonus. Mov Disord 1995 Jan; 10(1):22-7.
    View PubMed
  79. Matsumoto JY, Caviness JN, McEvoy KM. The acoustic startle reflex in stiff-man syndrome. Neurology 1994 Oct; 44(10):1952-5.
    View PubMed
  80. Muenter MD, Daube JR, Caviness JN, Miller PM. Treatment of essential tremor with methazolamide. Mayo Clin Proc 1991 Oct; 66(10):991-7.
    View PubMed
  81. Caviness JN, Muenter MD. An unusual cause of recurrent chorea. Mov Disord 1991; 6(4):355-7.
    View PubMed
  82. Caviness JN, Wightman RM. Use of rapid superfusion to differentiate the release of dopamine from striatal tissue induced by sympathomimetic amines from release induced by potassium. Journal of Pharmacology & Experimental Therapeutics 1982 Oct; 223(1):90-6.
    View PubMed
  83. Wightman RM, Bright CE, Caviness JN. Direct measurement of the effect of potassium, calcium, veratridine, and amphetamine on the rate of release of dopamine from superfused brain tissue. Life Sci 1981 Mar 16; 28(11):1279-86.
    View PubMed


Appointments Contact Us Make A Gift Search

Legal restrictions and terms of use applicable to this site

Use of this site signifies your agreement to the terms of use
Copyright © 2009 Mayo Foundation for Medical Education and Research.